In a perfect world insulin a life-saving medication for millions of people around the world would be free, but, at this point, heavily reduced costs are a great start. Danish drugmaker Novo Nordisk has announced it is joining the path of rival Eli Lily in lowering the price(s) of various types of insulin medications they presently have available. According to the company, the new pricing model is set to go into play on 1 January.
Here’s what to know.
This week the company announced that prefilled pens and vials of long- and short-acting insulins will see list steep price reductions. They include Levemir, Novolin, NovoLog, and NovoLog Mix 70/30. Unbranded products are also set to see price reductions.
A vial of their Novolog and NovoLog Mix 70/30 will drop a total of 75%, to $72.34 from $289.36. FlexPen options will fall to $139.71 from more than $500.